STOCKHOLM, SWEDEN--(Marketwired - April 08, 2013) - Mats-Olof Wallin has been appointed
interim Chief Financial Officer at Swedish
Orphan Biovitrum AB (Sobi). Wallin - until recently the CFO of Swedish
company Biotage AB (publ.) - brings more than 30 years of experience in the
pharmaceutical industry, gained from various executive positions within
companies such as Pharmacia, Ortivus and Biotage. Wallin has been working
Sobi for the past several months.
"We are glad to welcome Mats-Olof as interim CFO. Mats-Olof brings
experience to the role and will join our senior team in building a
company which brings value to all stakeholders", said CEO Geoffrey
Annika Muskantor, who has been interim CFO since August 2012, will support
Mats-Olof in his new role during a transition period.
Continued McDonough: "I would like to thank Annika for her excellent work
past year. She has built a strong financial platform which will continue to
support the development of this company."
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is
focused on inflammation and genetic diseases, with three late stage
development projects within hemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies.
a pioneer in biotechnology with world-class capabilities in protein
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9
(EUR 215 M) and about 480 employees. The share (STO: SOBI) is listed on
Stockholm. More information is available at www.sobi.com
Sobi press release April 8, 2013 in pdf version :
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE